Skip to main content

Table 3 The estimated ratio of the geometric mean number of days to recrudescence for each risk factor derived from linear regression analyses of 428 Plasmodium falciparum episodes among 354 pregnant women

From: Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort

   Univariablea Multivariablea
Risk factor Categories Nb Ratio of geometric means (95 % CI) [P-value] Nb Ratio of geometric means (95 % CI) [P-value]
Parity Primiparous 93 0.99 (0.86, 1.14) [0.890] 79 1.03 (0.89, 1.19) [0.698]
Multiparous 256 1c 212 1
Anti-malarial therapy Artemisinin based 49 1.28 (1.09, 1.51) [0.003] 38 1.24 (1.07, 1.43) [0.003]
Non-artemisinin based 300 1 253 1
Symptoms Symptomatic 232 0.89 (0.77, 1.03) [0.120] 211 0.94 (0.80, 1.11) [0.459]
Asymptomatic 88 1 80 1
Therapy supervision Unsupervised 86 0.83 (0.73, 0.94) [0.004] 81 0.83 (0.73, 0.95) [0.006]
Supervised 253 1 210 1
Intercalated P. vivax Yes 28 2.19 (1.77, 2.72) [<0.001] 25 2.19 (1.76, 2.73) [<0.001]
No 321 1 266 1
EGA (weeks) 349 349 1.00 (0.99, 1.00) [0.217] 291 1.00 (0.99, 1.00) [0.210]
Parasitaemia (m/L)d 349 349 0.98 (0.97, 1.00) [0.079] 291 0.98 (0.96, 0.99) [0.014]
Haematocrit (%) 327 327 1.00 (0.99, 1.01) [0.618] 291 1.00 (0.99, 1.01) [0.654]
  1. Combo, combination; Mono, monotherapy
  2. aOutcome is time to recrudescent infection and estimates are adjusted for age, weight and study period. Univariable, linear model included a single risk factor, age, weight and study period; Multivariable, linear model included all risk factors, age, weight and study period
  3. bThe total number of episodes (N) included in each analysis may differ from 428 due to missing risk factor data
  4. cIndicates reference group
  5. dParasitaemia was log2 transformed. Estimate interpreted as a 0.98-fold decrease in geometric mean time to recrudescent Pf infection(s) for a doubling in parasitaemia